Gilead Sciences (NASDAQ:GILD) Research Coverage Started at Truist Financial

Truist Financial began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Monday, Marketbeat reports. The firm issued a buy rating and a $140.00 target price on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Scotiabank started coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective on the stock. Daiwa Capital Markets boosted their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Morgan Stanley raised their price target on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Mizuho lifted their price target on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Trading Up 0.3%

NASDAQ GILD opened at $127.51 on Monday. The company has a market capitalization of $158.20 billion, a price-to-earnings ratio of 25.40, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a 12 month low of $88.57 and a 12 month high of $128.70. The company’s fifty day moving average price is $119.36 and its two-hundred day moving average price is $114.25.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the firm earned $2.02 EPS. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is 48.99%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the sale, the chief financial officer owned 154,555 shares in the company, valued at approximately $19,354,922.65. This represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. The trade was a 20.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 115,146 shares of company stock valued at $14,012,141 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in the company. Trivium Point Advisory LLC raised its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after acquiring an additional 83 shares in the last quarter. Binnacle Investments Inc grew its holdings in Gilead Sciences by 11.8% during the third quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares during the last quarter. Rothschild Investment LLC raised its position in shares of Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 84 shares during the period. Hemington Wealth Management lifted its stake in shares of Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares during the last quarter. Finally, Ignite Planners LLC boosted its holdings in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after buying an additional 86 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.